ObsEva (NASDAQ:OBSV) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of ObsEva (NASDAQ:OBSV) in a research report sent to investors on Friday morning. The firm issued a hold rating on the stock.

ObsEva Trading Down 100.0 %

The stock has a market cap of $7.94 million, a P/E ratio of -0.11 and a beta of 0.68. ObsEva has a 52-week low of $0.08 and a 52-week high of $2.14.

ObsEva Company Profile

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.